Yuyu Pharma Presents Poster on New Dry Eye Disease Drug Research at Global Ophthalmology Conference

[Asia Economy Reporter Lee Gwan-joo] Yuyu Pharma announced on the 4th that it presented a poster on the dry eye treatment peptide new drug 'YP-P10' at ARVO (The Association for Research in Vision and Ophthalmology), the world's largest ophthalmology conference.

YP-P10 is a biopharmaceutical using synthetic peptides, designed to be administered twice daily to treat dry eye syndrome by alleviating signs and symptoms caused by inflammation. In animal experiments, it demonstrated superior anti-inflammatory mechanisms and corneal epithelial cell healing effects compared to existing drugs.

Yoo Won-sang, CEO of Yuyu Pharma, said, "The YP-P10 research results, first presented at this ARVO conference, is a project that received FDA approval for phase 2 clinical trials last month in the United States, and we plan to administer the first dose to patients within the first half of the year."

ARVO, established in 1928, is the world's largest ophthalmology society with 12,000 research members from 75 countries. This year's 'ARVO 2022 Conference' is being held from June 1 to 4 (local time) in Denver, Colorado, USA.